Summary:
In adults with obesity-related HFpEF (BMI ≥30) from pooled STEP-HFpEF trials (n=1,145), stratified by baseline diuretic use, once-weekly semaglutide 2.4 mg for 52 weeks produced consistent weight reduction (-6.9% to -8.8%), greater symptom improvement in loop diuretic users (+9.3 vs +4.7 KCCQ points), and reduced loop diuretic doses by 17% compared to placebo (which showed 2.4% diuretic dose increase), with no significant safety signals across diuretic subgroups.
| PICO | Description |
|---|---|
| Population | Adults with obesity-related HFpEF (BMI ≥30), pooled STEP-HFpEF trials (n=1,145), stratified by diuretic use. |
| Intervention | Semaglutide 2.4 mg subcutaneously once weekly for 52 weeks plus standard HFpEF care. |
| Comparison | Matching placebo weekly for 52 weeks plus standard HFpEF care. |
| Outcome | Weight -6.9 to -8.8%. KCCQ +9.3 in loop diuretic users. Loop diuretic dose -17% vs +2.4%. No safety signals. |
Semaglutide & diuretic use in obesity-related HFpEF
Pooled RCT · obesity-related HFpEF · 52 weeks
Semaglutide gave consistent weight loss and symptom benefit across diuretic subgroups, with the largest KCCQ gain and a 17% loop-diuretic dose reduction in loop diuretic users.
Clinical Context
HFpEF affects half of heart failure cases and is increasingly recognized as obesity-driven. Chronic diuretic use carries electrolyte disturbances and renal deterioration.
Clinical Pearls
1. Loop Diuretic Users Derive Enhanced Benefit: Greatest symptomatic improvement in those requiring loop diuretics.
2. Diuretic Dose Reduction Represents Disease Modification: 17% reduction suggests favorable volume homeostasis remodeling.
3. Weight Loss Translates to Volume Improvement: Dual effect of adipose tissue reduction and decreased interstitial volume.
4. Safety Maintained Regardless of Baseline Diuretics: Favorable safety profiles across all diuretic subgroups.
Practical Application
Prioritize semaglutide in obesity-related HFpEF patients on loop diuretics. Reassess diuretic requirements as patients lose weight. Monitor potassium, creatinine, and volume status.
Study Limitations
Post-hoc pooled analysis. Diuretic adjustments per physician judgment. 52-week duration doesn’t address long-term outcomes.
Bottom Line
Semaglutide produces consistent benefits across diuretic subgroups, with loop diuretic users experiencing greatest improvement and 17% diuretic reduction.
Source: Jastreboff AM, et al. “Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction.” European Heart Journal. Read article